Full-Time

Quality Lead

Cooper Companies

Cooper Companies

201-500 employees

Global medical devices and vision care

Compensation Overview

$106.5k - $142k/yr

No H1B Sponsorship

Whiteley, UK + 2 more

More locations: Canandaigua, NY, USA | United Kingdom

In Person

Full-time onsite work (5 days/week) in Juana Diaz, PR, Victor, NY, or our UK office.

Bachelor's

Category
Manufacturing Quality & Test (1)
Required Skills
Veeva
Agile
Risk Management
Data Analysis

Get referred to Cooper Companies

See people who can refer or advise you

Requirements
  • Bachelor's degree in Engineering, Quality, Life Sciences, Biological Sciences, Business, or related technical discipline
  • Minimum 7 years of progressive Quality Assurance, Quality Systems, Compliance, or Quality Engineering experience within the medical device, pharmaceutical, biotechnology, or other regulated industry
  • Demonstrated experience managing or leading Quality System processes such as CAPA, Nonconformance, Complaints, Audits, Change Control, or Risk Management
  • Experience leading cross-functional improvement initiatives and driving process standardization efforts
  • Experience supporting regulatory inspections, certification audits, or internal audit programs
  • Proven ability to manage complex issues involving multiple stakeholders and business functions
  • Demonstrated understanding of medical device Quality Management Systems, regulatory requirements, and applicable standards (FDA 21 CFR Part 820, ISO 13485, EU MDR 2017/745, ISO 9001)
  • Strong expertise in Nonconformance, CAPA, Root Cause Analysis, Risk Management, and Continuous Improvement methodologies
  • Strong understanding of business process management, process governance, and process performance management principles
  • Experience working with electronic Quality Management Systems (eQMS) such as Veeva Vault, Agile, or equivalent systems
  • Experience developing KPIs, dashboards, scorecards, and data-driven performance monitoring systems
  • Strong analytical and problem-solving skills, with ability to interpret complex data and identify meaningful trends
  • Ability to assess regulatory changes and industry best practices and translate them into process improvements
  • Ability to influence stakeholders across multiple functions and global locations without direct reporting authority
  • Excellent communication, facilitation, presentation, and stakeholder management skills
  • Strong project and process management capabilities
  • Advanced proficiency with Microsoft Office applications and quality reporting tools
  • Fluent in English, both written and verbal. Additional languages are considered an asset
Responsibilities
  • Serve as the Global Process Owner for Nonconformance and CAPA processes across the enterprise Quality Management System
  • Accountable for the effectiveness, compliance, and continuous improvement of the global NC and CAPA processes, including performance metrics, investigation quality, CAPA effectiveness, and timely execution
  • Establish, maintain, and continuously improve global procedures, standards, workflows, templates, and governance requirements
  • Ensure NC and CAPA processes remain compliant with applicable regulations and standards by assessing documents of external origin and implementing necessary actions to maintain ongoing compliance
  • Lead periodic process reviews to assess effectiveness, compliance, efficiency, and alignment with business needs
  • Define and maintain global process ownership documentation, RACI models, and process maps
  • Ensure process harmonization and adoption across all sites, functions, and business units
  • Establish process governance mechanisms, escalation pathways, decision frameworks, and compliance monitoring activities
  • Monitor adherence to process requirements and drive remediation of identified gaps and noncompliance trends
  • Evaluate the impact of new regulatory requirements and industry best practices on NC and CAPA processes
  • Support internal audits, external audits, regulatory inspections, and management review activities related to process performance and compliance
  • Serve as the enterprise NC/CAPA Subject Matter Expert during regulatory inspections, Notified Body audits, MDSAP audits, customer audits, and certification assessments, ensuring effective process representation and inspection readiness
  • Partner with Quality Systems and IT teams to define and maintain NC and CAPA requirements within the eQMS platform
  • Lead business process requirements, workflow design, user acceptance testing, and system enhancement activities
  • Assess opportunities for automation, digitalization, and simplification while maintaining regulatory compliance
  • Support system deployments, upgrades, and validation activities impacting NC and CAPA functionality
  • Ensure process and system alignment throughout the lifecycle of the eQMS platform
  • Establish and monitor global performance indicators and quality system health metrics
  • Analyze process data and trends to identify systemic issues, recurring failures, and opportunities for improvement
  • Establish and promote enterprise root cause analysis methodologies and provide coaching to ensure effective and consistent problem-solving practices across the organization
  • Drive implementation of corrective and preventive improvements to enhance process performance, cycle times, and quality outcomes
  • Benchmark industry best practices and integrates appropriate improvements into the process framework
  • Lead global initiatives to improve CAPA effectiveness, investigation quality, and closure performance
  • Develop and maintain process training materials, guidance documents, and user support tools
  • Provide expert consultation and coaching to site and functional stakeholders regarding NC and CAPA requirements
  • Support organizational change management related to process updates and system enhancements
  • Facilitate global process owner forums, governance meetings, and stakeholder reviews
  • Build strong cross-functional partnerships to ensure effective process execution and continuous compliance
  • Develop dashboards, scorecards, and management reporting tools to monitor process performance
  • Analyze leading and lagging indicators to identify risks and improvement opportunities
  • Own enterprise reporting of NC and CAPA process performance and present performance trends, compliance risks, systemic issues, and improvement plans to executive leadership and governance bodies
  • Support Management Review processes through preparation and presentation of process health assessments
Desired Qualifications
  • Prior experience serving as a Global Process Owner or Lead Process Subject Matter Expert
  • Experience implementing or enhancing eQMS workflows and solutions
  • Operational Excellence, or Continuous Improvement experience
  • Experience working in a global, multi-site medical device organization
  • ASQ Certified Quality Engineer (CQE) or Certified Quality Auditor (CQA) or Certified Manager of Quality/Organizational Excellence (CMQ/OE) or equivalent certification
  • Lean Six Sigma Green Belt, PDCA, Kepner and Tregoe or equivalent continuous improvement certification
  • Experience with additional languages beyond English

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

1958

Get referred to Cooper Companies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 9, 2026 guidance raised fiscal 2026 revenue to $4.229-$4.252 billion.
  • MyDay MiSight and clariti launches are expanding across Japan, EMEA, and APAC.
  • Free cash flow reached $273 million in Q3 fiscal 2026, supporting $1 billion buybacks.

What critics are saying

  • CooperSurgical's 2023 embryo-media recall triggered $271.6 million charges and 140-plus lawsuits.
  • CooperVision's U.S. channel inventory reductions flattened Q3 revenue and cut fiscal guidance.
  • Persistent IVF safety concerns can permanently damage CooperSurgical's franchise with fertility clinics.

What makes Cooper Companies unique

  • CooperVision's MyDay daily silicone hydrogel portfolio drives premium contact-lens share globally.
  • CooperSurgical spans fertility, genomics, and women’s health, covering the reproductive-care workflow.
  • Cooper sells in 130-plus countries, pairing global distribution with vertically integrated manufacturing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Performance Bonus

Health Insurance

401(k) Retirement Plan

Life Insurance

Wellness Program

Professional Development Budget

Company News

Yahoo Finance
Sep 9th, 2026
CooperCompanies reports $1.08B Q1 revenue, up 7.9% year-on-year, beating estimates by 2.7%

CooperCompanies reported first-quarter revenues of $1.08 billion, up 7.9% year-on-year and exceeding analyst expectations by 2.7%. The medical device manufacturer, which focuses on vision care contact lenses and women's health products, also beat earnings per share estimates. The result came as the medical devices and supplies sector reported a strong quarter overall. Five tracked companies in the diversified category beat consensus revenue estimates by 2.9% on average, though next quarter's guidance came in 2.2% below expectations. Despite delivering the weakest full-year guidance update in the group, CooperCompanies' shares have risen 9% since reporting. The stock currently trades at $67.62.

Yahoo Finance
Sep 9th, 2026
Cooper Companies reports $271.8M record quarterly free cash flow, retains CooperSurgical after strategic review

Cooper Companies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1%, with non-GAAP earnings per share rising 4% to $1.15. The company generated record quarterly free cash flow of $273 million, bringing year-to-date free cash flow to $528 million, up 86% year over year. CooperVision revenue remained flat at $717 million due to planned US channel inventory reductions, though underlying consumer demand continued growing at mid-single digits. CooperSurgical posted 3% organic growth, with fertility revenue increasing 5% to $141 million. The board concluded its strategic review and decided to retain CooperSurgical, whilst authorising an additional $1 billion in share repurchases. For the fourth quarter, Cooper expects flat to 2% organic revenue growth and non-GAAP EPS of $1.05 to $1.09.

Yahoo Finance
Sep 9th, 2026
CooperCompanies misses Q2 revenue estimates by 2.9%, cuts full-year guidance, stock drops 16.8%

CooperCompanies reported second-quarter revenue of $1.07 billion, missing analyst estimates of $1.10 billion. The medical device company's sales were flat year-on-year, whilst its operating margin improved to 20.8% from 16.6% in the same quarter last year. The company lowered its full-year revenue guidance to $4.24 billion at the midpoint, down from $4.30 billion, representing a 1.5% decrease. Adjusted earnings per share guidance was also reduced to $4.53 at the midpoint, a 1.9% decrease. Despite beating analyst expectations with adjusted EPS of $1.15 versus estimates of $1.12, the company's shares fell 16.8% following the announcement. CEO Al White cited reduced US channel inventory at CooperVision as weighing on results. CooperCompanies develops medical devices for vision care and women's health.

Associated Press
Sep 9th, 2026
CooperCompanies Q3 revenue up 1% to $1.07B, nets $307M UK tax benefit

CooperCompanies reported third quarter fiscal 2026 revenue of $1.066 billion, up 1% year-over-year. The medical device company posted GAAP diluted earnings per share of $2.24, compared with $0.49 in the prior year quarter, primarily driven by a $307.2 million discrete tax benefit from a favourable UK tax examination completion. Non-GAAP diluted EPS reached $1.15, up 4% from last year. Free cash flow increased 66% to $273.0 million. The company repurchased $339.1 million of common stock during the quarter. CooperVision revenue was flat at $717.0 million, whilst CooperSurgical revenue rose 2% to $349.2 million, with 6% fertility growth. The company cited reduced US channel inventory at CooperVision impacting results. CooperCompanies updated its fiscal 2026 guidance, projecting total revenue of $4.229-$4.252 billion and non-GAAP diluted EPS of $4.51-$4.55.

Yahoo Finance
Jun 8th, 2026
Cooper Companies' international revenue rises 7.9% to $1.08B, with EMEA contributing $287M

The Cooper Companies reported total revenue of $1.08 billion for the quarter ending April 2026, up 7.9% year over year. International markets contributed significantly to this performance, with EMEA generating $289.7 million (26.8% of total revenue) and Asia Pacific adding $130.6 million (12.1%). EMEA revenue exceeded Wall Street expectations by 5.18%, whilst Asia Pacific fell marginally short by 0.17%. The surgical and contact lens products maker's EMEA performance represented growth from $248.6 million in the year-ago quarter, though Asia Pacific revenue declined from $138.6 million over the same period. For the current fiscal quarter, analysts project total revenue of $1.12 billion, with EMEA expected to contribute $305.46 million and Asia Pacific $143.73 million.